Author Archives: admin

Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection

Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection Kaitlyn Bader, Senior Editor NEWS PROVIDED BY Alphyn Biologics July 14, 2023 AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component. Read the Dermatology Times article…

Healio: AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis

Healio: AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis by Gabrielle Capaldo NEWS PROVIDED BY Alphyn Biologics July 14, 2023 53.3% of pediatric patients treated with AB-101a achieved a 1-point decrease in IGA vs. 0% of those treated with vehicle. This outcome was also seen in 60% of…

Society for Pediatric Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild, Moderate, and Severe Atopic Dermatitis

Society for Pediatric Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild, Moderate, and Severe Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics July 13, 2023, 19:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Dermatology Times: Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis

Dermatology Times: Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis Heather Raglin, Editor NEWS PROVIDED BY Alphyn Biologics July 11, 2023 Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon. Read the Dermatology Times article here. CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com…

World Congress of Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis

World Congress of Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics July 6, 2023, 10:00 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

European Society for Pediatric Dermatology Poster Presentation: Pediatric Data from Phase 2a Trial of AB-101a for Mild-to-Moderate Atopic Dermatitis

European Society for Pediatric Dermatology Poster Presentation: Pediatric Data from Phase 2a Trial of AB-101a for Mild-to-Moderate Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics May 4, 2023, 07:25 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195